Open AccessGonadotrophin releasing hormone agonist with low dose human chorionic gonadotrophin co-triggers versus gonadotrophin releasing hormone agonist alone for reducing the risk of ovarian hyperstimulation in women with polycystic ovarian disease.
Author(s) -
Ahmed Arafa,
Mohamed Mokhtar Mohamed,
Ahmed Aboulserour,
Mohamed Gebreel
Publication year - 2022
Publication title -
al-azhar international medical journal /al-azhar international medical journal
Language(s) - English
Resource type - Journals
eISSN - 2682-339X
pISSN - 2682-3381
DOI - 10.21608/aimj.2022.117755.1810
Subject(s) - polycystic ovarian disease , agonist , ovarian hyperstimulation syndrome , controlled ovarian hyperstimulation , gonadotropin releasing hormone agonist , medicine , polycystic ovary , in vitro fertilisation , human chorionic gonadotropin , intracytoplasmic sperm injection , hormone , gonadotropin releasing hormone , endocrinology , biology , luteinizing hormone , pregnancy , receptor , insulin resistance , genetics , insulin